Probiotic colonization dynamics after oral consumption of VSL#3^® by antibiotic-treated mice

Abstract

Background: The ability of probiotic strains to provide health benefits to the host partially hinges on the survival of gastrointestinal passage and temporary colonization of the digestive tract. This study aims to investigate the colonization profile of individual probiotic strains comprising the commercial product VSL#3^® and determine their impact on the host intestinal microbiota.

Methods: Using a cefoperazone-treated mouse model of antibiotic treatment, we investigated the impact of oral gavage with ~10⁸ CFU commercial VSL#3^® product on the intestinal microbiota using 16S-based amplicon sequencing over 7 days.

Results: Results showed that probiotic strains in the formulation were detected in treated murine fecal samples, with early colonization by Streptococcus thermophilus and Lactiplantibacillus plantarum subsp. plantarum, and late colonization by Lacticaseibacillus paracasei subsp. paracasei, Bifidobacterium breve and Bifidobacterium animalis subsp. lactis. Overall, VSL#3^® consumption is associated with increased alpha diversity in the cecal microbial community, which is important in the context of antibiotic consumption. Probiotic supplementation resulted in an expansion of Proteobacteria, Bacteroidetes, and Actinobacteria, especially Bifidobacteriaceae and Lachnospiraceae, which are associated with Clostridioides difficile resistance in the murine gut.

Conclusion: This study illustrates the need for determining the ability of probiotics to colonize the host and impact the gut microbiota, and suggests that multiple doses may be warranted for extended transient colonization. In addition, follow-up studies should determine whether VSL#3^® can provide resistance against C. difficile colonization and disease in a mouse model.

Keywords

Probiotics / antibiotics / colonization / microbiota

References

[1] Lynch SV.The human intestinal microbiome in health and disease.N Engl J Med2016;375:2369-79

[2] Theriot CM.Interactions between the gastrointestinal microbiome and clostridium difficile.Annu Rev Microbiol2015;69:445-61 PMCID:PMC4892173

[3] Knight R,Taylor BC.Best practices for analysing microbiomes.Nat Rev Microbiol2018;16:410-22

[4] Aggarwala V,Li Z.Precise quantification of bacterial strains after fecal microbiota transplantation delineates long-term engraftment and explains outcomes.Nat Microbiol2021;6:1309-18 PMCID:PMC8993687

[5] Seekatz AM,Santhosh K.Dynamics of the fecal microbiome in patients with recurrent and nonrecurrent Clostridium difficile infection.Genome Med2016;8:47 PMCID:PMC4847246

[6] Seekatz AM,Gessert CE.Recovery of the gut microbiome following fecal microbiota transplantation.mBio2014;5:e00893-14 PMCID:PMC4068257

[7] Smillie CS,Gevers D.Strain tracking reveals the determinants of bacterial engraftment in the human gut following fecal microbiota transplantation.Cell Host Microbe2018;23:229-240.e5 PMCID:PMC8318347

[8] Faith JJ,Charbonneau M.The long-term stability of the human gut microbiota.Science2013;341:1237439 PMCID:PMC3791589

[9] Poyet M,Gibbons SM.A library of human gut bacterial isolates paired with longitudinal multiomics data enables mechanistic microbiome research.Nat Med2019;25:1442-52

[10] Qin J,Raes J.MetaHIT ConsortiumA human gut microbial gene catalogue established by metagenomic sequencing.Nature2010;464:59-65 PMCID:PMC3779803

[11] Suez J,Zilberman-Schapira G.Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT.Cell2018;174:1406-1423.e16

[12] Zmora N,Suez J.Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features.Cell2018;174:1388-1405.e21

[13] Callahan BJ,Heiner C.High-throughput amplicon sequencing of the full-length 16S rRNA gene with single-nucleotide resolution.Nucleic Acids Res2019;47:e103 PMCID:PMC6765137

[14] Theriot CM,Carlson PE,Aronoff DM.Cefoperazone-treated mice as an experimental platform to assess differential virulence of Clostridium difficile strains.Gut Microbes2011;2:326-34 PMCID:PMC3337121

[15] Theriot CM,Carlson PE Jr.Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection.Nat Commun2014;5:3114 PMCID:PMC3950275

[16] Theriot CM,Young VB.Antibiotic-induced alterations of the gut microbiota alter secondary bile acid production and allow for clostridium difficile spore germination and outgrowth in the large intestine.mSphere2016;1:e00045-15 PMCID:PMC4863611

[17] Panetta V,Papetti S,Navarra P.The safety profile of probiotic VSL#3^®. A meta-analysis of safety data from double-blind, randomized, placebo-controlled clinical trials.Eur Rev Med Pharmacol Sci2021;25:6443

[18] Douillard FP,Eijlander RT,de Vos WM.Comparative genomic analysis of the multispecies probiotic-marketed product VSL#3.PLoS One2018;13:e0192452 PMCID:PMC5815585

[19] Ankersen DV,Bennedsen M.Long-term effects of a web-based low-fodmap diet versus probiotic treatment for irritable bowel syndrome, including shotgun analyses of microbiota: randomized, double crossover clinical trial.J Med Internet Res2021;23:e30291 PMCID:PMC8715363

[20] Laterza L,Petito V,Gaetani E.Evaluation of tolerability and major factors affecting the adherence to probiotic therapy in patients with irritable bowel syndrome: a prospective, observational, real-life study.Minerva Med2021;

[21] Derosa G,D’Angelo A.Probiotic therapy with VSL#3^® in patients with NAFLD: a randomized clinical trial.Front Nutr2022;9:846873 PMCID:PMC9172906

[22] Singh G,Briscoe L.The effect of gastric acid suppression on probiotic colonization in a double blinded randomized clinical trial.Clin Nutr ESPEN2022;47:70-7

[23] Cancello R,Rampelli S.Effect of short-term dietary intervention and probiotic mix supplementation on the gut microbiota of elderly obese women.Nutrients2019;11:3011 PMCID:PMC6950529

[24] Callahan BJ,Rosen MJ,Johnson AJ.DADA2: high-resolution sample inference from Illumina amplicon data.Nat Methods2016;13:581-3 PMCID:PMC4927377

[25] Callahan BJ,Fukuyama JA,Holmes SP.Bioconductor workflow for microbiome data analysis: from raw reads to community analyses.F1000Res2016;5:1492 PMCID:PMC4955027

[26] McMurdie PJ.Phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data.PLoS One2013;8:e61217 PMCID:PMC3632530

[27] Fernandes AD,Macklaim JM,Edgell DR.Unifying the analysis of high-throughput sequencing datasets: characterizing RNA-seq, 16S rRNA gene sequencing and selective growth experiments by compositional data analysis.Microbiome2014;2:15 PMCID:PMC4030730

[28] Dethlefsen L.Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation.Proc Natl Acad Sci U S A2011;108 Suppl 1:4554-61 PMCID:PMC3063582

[29] Laursen MF,von Burg N.Bifidobacterium species associated with breastfeeding produce aromatic lactic acids in the infant gut.Nat Microbiol2021;6:1367-82 PMCID:PMC8556157

[30] Vangay P,Gerber JS.Antibiotics, pediatric dysbiosis, and disease.Cell Host Microbe2015;17:553-64 PMCID:PMC5555213